AA
Therapeutic Areas
Concept Medical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Sirolimus-Coated Balloon (SCB) - en-ABL Series | Coronary Artery Disease, All-comer lesions | Commercial (Post-market) |
| Drug-Eluting Stent (DES) - Ability Series | Coronary Artery Disease in Diabetes Mellitus | Phase 3 |
| Sirolimus-Coated Balloon (SCB) - Nanolute Series | De novo lesions, In-Stent Restenosis (ISR), Small Vessel, Bifurcation | Commercial (Post-market) |
| Sirolimus-Coated Balloon (SCB) - DEDICATE Registry | Diabetes Mellitus | Registry |
| Sirolimus-Coated Balloon (SCB) - CUT-DRESS RCT | Diabetes Mellitus (Pre-dilation strategy) | Phase 3 |
| Sirolimus-Coated Balloon (SCB) - Transform II | Native Coronary Vessel Disease (vs. EES) | Phase 3 |
| Sirolimus-Coated Balloon (SCB) - Titan | Native Coronary Vessel Disease (vs. DES) | Phase 3 |
| Sirolimus-Coated Balloon (SCB) - Hybrid Bifurcation PCI | Coronary Bifurcation Lesion | Phase 3 |
Leadership Team at Concept Medical
SD
Sameer Dani
Principal Investigator (en-ABL Studies)
AL
Azeem Latib
Principal Investigator (Ability RCT)
AC
Antonio Colombo
Principal Investigator & Study Chairperson (Ability Studies)
SK
Santosh Kumar Sinha
Principal Investigator (en ABL Advance)
LT
Luca Testa
Principal Investigator (DEDICATE)
JS
Jorge Sanz Sanchez
Principal Investigator (CUT-DRESS Studies)